The effects of 1L infusions of 0.9% saline and Voluven® on plasma volume, serum biochemistry and sodium and water controlling hormones in healthy volunteers: a double blind, randomised crossover study

Submission date	Recruitment status No longer recruiting	Prospectively registered		
29/09/2006		Protocol		
Registration date 29/09/2006	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	Individual participant data		
28/09/2011	Other			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr K L Ingram

Contact details

University Department of Anaesthesia C Floor East University Hospital Nottingham United Kingdom NG7 2UH

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0192165308

Study information

Scientific Title

Study objectives

To study the responses of normal volunteers to 1 litre infusions of 0.9% saline and Voluven® over 1 hour. In particular the extent and time course of the effects of the two infusions on haematocrit, serum albumen, serum biochemistry, plasma expanding capacity and the resultant urinary responses will be measured.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Double blind, randomised crossover study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Effects of Voluven® infusion on plasma volume, serum biochemistry and sodium and water controlling hormones

Interventions

Double blind, randomised crossover study

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

saline and Voluven®

Primary outcome measure

Difference in effects produced by the two infusions on haemotocrit, serum albumin, chloride, osmolality, AVP, renin, ANP and aldosterone. Differences betwen the infusions will be tested for statistical significance using the Wilcoxon signed ranks test and repeated measures ANOVA. Differences will be considered significant if P<0.05.

Secondary outcome measures

Not provided at time of registration

Overall study start date

27/06/2005

Completion date

27/03/2006

Eligibility

Key inclusion criteria

Male subjects aged between 18 and 40 years responding to local advertisement will be screened by questionnaire and medical examination before being chosen.

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Male

Target number of participants

10

Key exclusion criteria

Subjects weighing less than 65kg or more than 80kg, those with medical conditions or allergies, those on regular medications, and participants in a study less than three months before will be excluded.

Date of first enrolment

27/06/2005

Date of final enrolment

27/03/2006

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
University Department of Anaesthesia
Nottingham
United Kingdom
NG7 2UH

Sponsor information

Organisation

Record Provided by the NHSTCT Register - 2006 Update - Department of Health

Sponsor details

The Department of Health, Richmond House, 79 Whitehall London United Kingdom SW1A 2NL +44 (0)20 7307 2622 dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type

Government

Funder Name

Queen's Medical Centre University Hospital NHS Trust (UK)

Funder Name

NHS R&D Support Funding

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2010		Yes	No